Discovery of a Novel and Potent Cyclin-Dependent Kinase 8/19 (CDK8/19) Inhibitor for the Treatment of Cancer-Reference-Cited by-同舟云学术

Discovery of a Novel and Potent Cyclin-Dependent Kinase 8/19 (CDK8/19) Inhibitor for the Treatment of Cancer

Published:2024-05-01 Issue:10 Volume:67 Page:8161-8171
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Xu Jianyu¹,Qi Hongyun¹,Wang Zhen¹,Wang Ling¹,Steurer Barbara²,Cai Xin¹,Liu Jinxin¹,Aliper Alex³^ORCID,Zhang Man¹,Ren Feng¹^ORCID,Zhavoronkov Alex¹³^ORCID,Ding Xiao¹^ORCID

Affiliation:

1. Insilico Medicine Shanghai Ltd, Suite 902, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New District, Shanghai 201203, China

2. Insilico Medicine Hong Kong Ltd., Hong Kong Science and Technology Park, Hong Kong 999077, China

3. Insilico Medicine AI Limited, Masdar City, Abu Dhabi 145748, UAE

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c00248

Reference44 articles.

1. CDK8 and CDK19: positive regulators of signal-induced transcription and negative regulators of Mediator complex proteins

2. CDK8 Kinase Phosphorylates Transcription Factor STAT1 to Selectively Regulate the Interferon Response

3. CDK8 Selectively Promotes the Growth of Colon Cancer Metastases in the Liver by Regulating Gene Expression of TIMP3 and Matrix Metalloproteinases

4. The Inhibition of CDK8/19 Mediator Kinases Prevents the Development of Resistance to EGFR-Targeting Drugs

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Artificial intelligence integration in the drug lifecycle and in regulatory science: policy implications, challenges and opportunities;Frontiers in Pharmacology;2024-08-02